drugset / Trial / NCT04378647
BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant
RandomizedParallel-groupOpen-labelTreatment
Summary
A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin's Lymphoma, Followed by Brentuximab Vedotin Consolidation (instead of Autologous Hematopoietic Stem Cell Transplantation) in Those who Attained a Metabolic Complete Remission after Salvage Therapy
Timeline
- Start
- 2020-06-01
- Primary completion
- 2026-08-30
- Completion
- 2026-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brentuximab Vedotin | Monoclonal antibody | 1.8 mg/kg | Intravenous |
| Comparator | Cisplatin | Other / unclassified | 25 mg/m2 | Intravenous |
| Comparator | Cytarabine | Small molecule | 2 g | Intravenous |
| Comparator | Etoposide | Small molecule | 40 mg/m2 | Intravenous |
| Comparator | Methylprednisolone | Other / unclassified | 250 mg | Intravenous |